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AbSTrACT
Objectives To determine whether progressive skin 
fibrosis is associated with visceral organ progression 
and mortality during follow-up in patients with diffuse 
cutaneous systemic sclerosis (dcssc).
Methods We evaluated patients from the european 
scleroderma Trials and Research database with dcssc, 
baseline modified Rodnan skin score (mRss) ≥7, valid 
mRss at 12±3 months after baseline and ≥1 annual 
follow-up visit. Progressive skin fibrosis was defined as 
an increase in mRss >5 and ≥25% from baseline to 
12±3 months. Outcomes were pulmonary, cardiovascular 
and renal progression, and all-cause death. associations 
between skin progression and outcomes were evaluated 
by Kaplan-Meier survival analysis and multivariable Cox 
regression.
results Of 1021 included patients, 78 (7.6%) had 
progressive skin fibrosis (skin progressors). Median 
follow-up was 3.4 years. survival analyses indicated that 
skin progressors had a significantly higher probability 
of FVC decline ≥10% (53.6% vs 34.4%; p<0.001) 
and all-cause death (15.4% vs 7.3%; p=0.003) than 
non-progressors. These significant associations were 
also found in subgroup analyses of patients with either 
low baseline mRss (≤22/51) or short disease duration 
(≤15 months). in multivariable analyses, skin progression 
within 1 year was independently associated with FVC 
decline ≥10% (HR 1.79, 95% Ci 1.20 to 2.65) and all-
cause death (HR 2.58, 95% Ci 1.31 to 5.09).
Conclusions Progressive skin fibrosis within 1 year 
is associated with decline in lung function and worse 
survival in dcssc during follow-up. These results confirm 
mRss as a surrogate marker in dcssc, which will be 
helpful for cohort enrichment in future trials and risk 
stratification in clinical practice.
InTrOduCTIOn
Systemic sclerosis (SSc) is a highly heterogeneous 
connective tissue disease with major morbidity and 
mortality caused by the development of visceral 
organ complications. These include interstitial 
lung fibrosis, pulmonary arterial hypertension, 
scleroderma renal crisis (SRC), and cardiac and 
gastrointestinal involvement.1 A major challenge 
for physicians is to identify patients at high risk 
of future complications before irreversible visceral 
involvement occurs. With several new disease-mod-
ifying agents in late-stage development,2 improved 
identification of at-risk patients will become even 
more important to inform early treatment interven-
tion. In addition, it will provide important informa-
tion for cohort enrichment in future clinical trials.3
Skin fibrosis is a hallmark of SSc. The modified 
Rodnan skin score (mRSS) rates skin thickness from 
0 (normal) to 3 (severe) at 17 body surface areas in 
a standardised manner.4 The mRSS is feasible, reli-
able and sensitive to change, and is now commonly 
used in routine practice and clinical trials.5–7
Using the European Scleroderma Trials and 
Research (EUSTAR) database, we previously iden-
tified short disease duration (≤15 months) and low 
baseline mRSS (≤22/51) as independent predictors 
of progressive skin fibrosis (defined as >5 units and 
≥25% increment in mRSS at 1-year follow-up) in 
patients with diffuse cutaneous SSc (dcSSc).8 9 While 
Key messages 
What is already known about this subject?
 ► Recent evidence-based clinical trial design 
aimed at including patients with high risk for 
progression of skin fibrosis.
 ► However, it is unclear, whether mRSS 
progression is an appropriate surrogate marker 
for new onset or deterioration of visceral organ 
disease and mortality in SSc.
What does this study add?
 ► Using the large EUSTAR cohort, this study could 
show that mRSS progression within 1 year is 
associated with long-term lung deterioration, 
overall disease progression and all-cause 
mortality.
How might this impact on clinical practice?
 ► Patients with short term progressive skin 
disease should be carefully monitored for other 
organ progression in the following years.
 ► The results show that mRSS progression is 
an excellent surrogate marker for long-term 
disease progression in SSc, which supports the 
use of mRSS as an end point in clinical trials.
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this evidence-based strategy of including patients with dcSSc 
with low baseline mRSS can improve cohort enrichment for 
progressive skin fibrosis in clinical trials,10 it might lead to 
recruitment of patients with overall milder disease. Previous 
studies have suggested that mRSS may be a potential surrogate 
marker for disease severity and mortality, but these data were 
derived from older studies and/or selected patients from clinical 
trials (D-penicillamine).11 12 Therefore, new data are required to 
clarify whether worsening skin fibrosis is an appropriate surro-
gate marker for new onset or deterioration of visceral organ 
disease and overall survival in dcSSc.
In a previous single-centre retrospective study of patients with 
early dcSSc, patients with high baseline mRSS and no subse-
quent skin improvement within 2 years had significantly higher 
mortality than those with skin improvement irrespective of base-
line mRSS, while the results for internal organ-based endpoints 
were contradictory.13 The study thus suggested the prognostic 
value of the evolution of skin fibrosis, in addition to absolute skin 
scores, in predicting disease outcome for patients with dcSSc. We 
herein hypothesise that progression of skin fibrosis within 1 year 
might be associated with progression of visceral organ disease 
and mortality in dcSSc during follow-up. The aim of the current 
study was to test this hypothesis in the large, systematic, longitu-
dinal, real-life EUSTAR registry.
MeTHOdS
More details on methods can be found in the online supplement.
Patients and study design
For this observational study, data from patients’ visits from 
1 January 2009 to 31 August 2017 were exported from the 
EUSTAR database. The structure of the EUSTAR database and 
minimum essential dataset have been described previously.14 15
Inclusion criteria for the study were classification of SSc (1980 
American College of Rheumatology criteria16), diffuse cutaneous 
involvement as described by LeRoy et al,17 at least one available 
annual follow-up visit, mRSS ≥7 (the minimal value for subclas-
sification as dcSSc) at the first available visit (baseline) and valid 
mRSS data at 12±3 months after baseline.
definition of ‘progressor’ patients
Patients with progression of skin fibrosis (skin progressors) 
were defined as those with an increase in mRSS >5 units and 
by ≥25% from baseline to 12±3 months. This mRSS threshold 
is considered as the minimally clinical important difference.18 
The 1-year period to define skin progression was chosen as it is 
considered sufficient to capture significant changes in mRSS and 
is thus frequently used in clinical trials in skin fibrosis.19
Follow-up and outcome measures
Follow-up was defined as the time between the first available 
visit (baseline) and the last available annual follow-up for each 
patient. All outcome events were accounted during this period. 
Outcome measures reflecting visceral organ progression were 
defined by consensus of an expert group (YA, MM-C, JEP, CPD, 
DK and OD) using the nominal group technique. Organ progres-
sion was defined as occurrence of one of the following events 
during follow-up: (1) relative decrease in FVC ≥10% from base-
line; (2) reduction of left ventricular ejection fraction (LVEF) 
to <45%, or relative decrease of LVEF >10% for patients 
with baseline LVEF <45%, assessed by echocardiography; (3) 
new-onset pulmonary hypertension (PH) as globally judged on 
echocardiography by the treating physician; (4) new-onset SRC; 
(5) all-cause death.20–23 Overall disease progression was defined 
as the presence of any of the above outcomes. In addition, an 
exploratory analysis in which lung progression was defined as a 
relative decrease from baseline to follow-up in FVC ≥10%, or 
5%–9% combined with diffusing capacity for carbon monoxide 
(DLCO) ≥15% (instead of definition 1), was performed based 
on recently proposed criteria.24
Statistical analysis
Baseline characteristics were described as mean (SD) for contin-
uous variables and number (frequency) for categorical variables. 
Baseline variables were compared between skin progressors and 
non-progressors by univariate analysis followed by Bonferroni 
correction. Chi-squared tests or Fisher’s exact tests were used 
for categorical variables, and independent sample t-tests were 
used for continuous variables.
Kaplan-Meier curves and log-rank tests were performed to 
compare outcomes between skin progressors and non-progres-
sors for up to 8 years of follow-up. Only the first event was 
considered. Patients with PH or SRC at baseline were excluded 
from analyses of PH and SRC outcomes, as these patients could 
not show any new event of these types. Kaplan-Meier analyses 
were also conducted in subgroups stratifying patients by either 
baseline mRSS (≤22/51 vs >22/51 units) or disease duration 
(≤15 vs >15 months). Multivariable Cox regression analyses 
were performed to examine independent associations between 
skin progression and both FVC decline ≥10% and all-cause 
death. Confounding variables for multivariable Cox regres-
sion models were selected using the nominal group technique. 
Spearman rho analyses were conducted to measure the correla-
tion between variables before multivariable regression. Multiple 
imputation with 10 imputed datasets was used before regression 
analysis to handle missing values.
Significance was defined as p value <0.05. Statistical analyses 
were performed by the biostatistician (NG) using R program-
ming language (V.3.3.3), packages ‘survival’ and ‘mice’.25–27
reSulTS
baseline characteristics
In total, 1021 patients were included for analysis, of whom 78 
(7.6%) had progression of skin fibrosis at 1-year follow-up. 
Demographic and clinical characteristics are summarised in 
table 1. Mean age was 52.0 years, mean disease duration was 7.7 
years and mean±SD mRSS was 16.9±7.7 at baseline. Median 
follow-up was 3.4 years. By using Bonferroni correction, the 
modified critical p value (α) was determined as 0.0013. Skin 
progressors had a significantly shorter disease duration at base-
line than non-progressors, confirming previous results.8 9 All 
other baseline characteristics were comparable between groups 
(table 1).
Associations between skin progression and visceral organ 
progression
Lung progression
In total, 282 of 788 patients (35.8%) met the FVC definition 
of lung progression (relative decrease in FVC ≥10%) during a 
median follow-up of 3.7 years (IQR 1.8–6.2 years). In the overall 
cohort, 403 of 670 patients (60.1%) had lung fibrosis on CT scan 
at baseline. The mean±SD FVC at baseline was 86.9%±20.5%, 
with 164 patients (20.8%) having a baseline FVC <70%. There 
were 30 (53.6%) and 252 (34.4%) events in the skin progressor 
and non-progressor groups, respectively. The probability of 
FVC decline was significantly higher for skin progressors than 
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Table 1 Baseline demographic and clinical characteristics of skin progressors and non-progressors
Characteristics Missing cases, n (%) Whole cohort (n=1021) Progressors (n=78) non-progressors (n=943) P value
Demographic 
  Age, years (mean±SD) 0 (0) 52.0±13.7 51.7±12.9 52.0±13.7 0.869
  Male sex 0 (0) 248 (24.3) 30 (38.5) 218 (23.1) 0.004
  Disease duration* years (mean±SD) 78 (7.6) 7.7±7.5 5.3±6.2 7.9±7.5 0.006
  ≤15 months 78 (7.6) 126 (13.4) 19 (27.9) 107 (12.2) <0.001
  ≤36 months 78 (7.6) 298 (31.6) 36 (52.9) 262 (29.9) <0.001
Vascular 
  Raynaud’s phenomenon 2 (0.2) 997 (97.8) 74 (94.9) 923 (98.1) 0.141
  Digital ulcers 11 (1.1) 384 (38.0) 30 (38.5) 354 (38.0) 1.000
  Active digital ulcers 25 (2.4) 199 (20.0) 16 (21.1) 183 (19.9) 0.925
Skin 
  mRSS, unit (mean±SD) 0 (0) 16.9±7.7 14.8±6.2 17.1±7.7 0.010
  mRSS ≤22/51 0 (0) 819 (80.2) 67 (85.9) 752 (79.7) 0.245
Musculoskeletal 
  Tendon friction rubs 11 (1.1) 156 (15.4) 10 (13.0) 146 (15.6) 0.648
  Joint synovitis 6 (0.6) 180 (17.7) 16 (20.5) 164 (17.5) 0.607
  Joint contractures 7 (0.7) 505 (49.8) 42 (53.8) 463 (49.5) 0.532
  Muscle weakness 6 (0.6) 255 (25.1) 17 (22.1) 238 (25.4) 0.614
Gastrointestinal 
  Oesophageal symptoms 1 (0.1) 687 (67.4) 51 (65.4) 636 (67.5) 0.795
  Stomach symptoms 2 (0.2) 300 (29.4) 27 (34.6) 273 (29.0) 0.361
  Intestinal symptoms 3 (0.3) 281 (27.6) 21 (26.9) 260 (27.7) 0.994
Cardiopulmonary 
  Dyspnoea (NYHA) 84 (8.2) 0.186
  Stage 1 520 (55.5) 34 (51.5) 486 (55.8)
  Stage 2 315 (33.6) 28 (42.4) 287 (33.0)
  Stage 3/4 102 (10.9) 4 (6.1) 98 (11.2)
  Diastolic dysfunction 150 (14.7) 195 (22.4) 12 (18.5) 183 (22.7) 0.526
  Pericardial effusion 215 (21.1) 59 (7.3) 7 (12.1) 52 (7.0) 0.238
  Conduction blocks 124 (12.1) 123 (13.7) 6 (8.8) 117 (14.1) 0.300
  LVEF <45% 266 (26.1) 16 (2.1) 2 (3.4) 14 (2.0) 0.797
  Pulmonary hypertension byechocardiography† 138 (13.5) 120 (13.6) 11 (16.7) 109 (13.3) 0.568
  Lung fibrosis on CT scan 351 (34.4) 403 (60.1) 33 (60.0) 370 (60.2) 1.000
  FVC, % predicted (mean±SD) 168 (16.5) 87.0±20.7 86.6±17.5 87.0±20.9 0.879
  FVC <70% predicted 168 (16.5) 182 (21.3) 13 (21.7) 169 (21.3) 1.000
  FEV
1, % predicted (mean±SD) 272 (26.6) 85.7±18.4 87.2±16.5 85.6±18.6 0.547
  TLC, % predicted (mean±SD) 427 (41.8) 86.6±20.6 86.5±15.3 86.6±20.9 0.991
  DLCO, % predicted (mean±SD) 179 (17.5) 65.6±19.3 65.6±17.2 65.6±19.4 0.995
  DLCO <70% predicted 179 (17.5) 479 (56.9) 33 (57.9) 446 (56.8) 0.984
Kidney 
  Renal crisis history 4 (0.4) 30 (2.9) 2 (2.6) 28 (3.0) 1.000
Laboratory parameters 
  ANA positive 16 (1.6) 961 (95.6) 75 (96.2) 886 (95.6) 1.000
  ACA positive 64 (6.3) 88 (9.2) 6 (8.2) 82 (9.3) 0.929
  Anti-Scl-70 positive 42 (4.1) 616 (62.9) 49 (66.2) 567 (62.7) 0.628
  Anti-U1RNP positive 237 (23.2) 35 (4.5) 1 (1.6) 34 (4.7) 0.514
  Anti-RNA polymerase III positive 453 (44.4) 58 (10.2) 5 (9.8) 53 (10.3) 1.000
  Creatinine kinase elevation 75 (7.3) 100 (10.6) 8 (10.8) 92 (10.6) 1.000
  Proteinuria 78 (7.6) 64 (6.8) 5 (6.9) 59 (6.8) 1.000
  Hypocomplementaemia 192 (18.8) 58 (7.0) 3 (4.8) 55 (7.2) 0.613
  ESR >25 mm/h 117 (11.5) 371 (41.0) 24 (35.3) 347 (41.5) 0.382
  CRP elevation 63 (6.2) 294 (30.7) 31 (41.9) 263 (29.8) 0.041
  Active disease (VAI >3)‡ 154 (15.1) 340 (39.2) 20 (30.8) 320 (39.9) 0.187
  Immunosuppressive therapy§ 66 (6.5) 667 (69.8) 54 (73.0) 613 (69.6) 0.632
Definitions of items and organ manifestation are according to EUSTAR.14
Data are presented as number (%) unless otherwise stated.
P values of univariate comparisons of baseline characteristics between skin progressors and non-progressors are shown (χ2 tests or Fisher’s exact tests used for categorical variables  
and independent sample t-tests used for continuous variables, as appropriate).
*Disease duration was calculated as the difference between the date of the baseline visit and the date of the first non-Raynaud’s symptom of the disease as reported by the patient.
†Pulmonary hypertension was globally judged on echocardiography by the treating physician.
‡Active disease was defined as a score >3 by calculating European Scleroderma Study Group disease activity indices for systemic sclerosis proposed by Valentini et al.45
§Immunosuppressive therapy was defined as treatment with corticosteroids (prednisone dose ≥2.5 mg/day or other dosage forms in equal dose) or any immunosuppressant.
ACA, anti-centromere antibody; ANA, antinuclear antibody; Anti-Scl-70, anti-topoisomerase 1 antibody; CRP, C reactive protein;CT, computed tomography; DLCO, diffusing capacity for carbon monoxide; ESR, erythrocyte 
sedimentation rate; FEV1, forced expiratory volume in 1 sec; FVC, forced vital capacity; LVEF, left ventricular ejection fraction;mRSS, modified Rodnan skin score.NYHA, New York Heart Association; TLC, total lung capacity; VAI, 
Valentini activity index;
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Figure 1 Kaplan-Meier survival plots for (A) time to FVC decline ≥10%, (B) time to FVC-DCLO composite endpoint, (C) time to all-cause death and 
(D) time to overall disease progression during follow-up depending on the presence or absence of skin progression within 1 year. DLCO, diffusing 
capacity for carbon monoxide; FVC, forced vital capacity.
Figure 2 Kaplan-Meier survival plots for FVC decline ≥10% during follow-up depending on the presence or absence of skin progression within 1 
year in subgroups of patients with (A) baseline mRSS ≤22/51 units, (B) baseline mRSS >22/51 units, (C) disease duration ≤15 months and (D) disease 
duration >15 months. FVC, forced vital capacity; mRSS, modified Rodnan skin score.
non-progressors (log-rank test p<0.001; figure 1A). In the 
subgroups of patients with low baseline mRSS and short disease 
duration, which reflect evidence-based recruitment parameters 
for recent clinical trials in skin fibrosis,8 skin progressors also 
had a significantly higher probability of FVC decline than 
non-progressors (baseline mRSS ≤22/51 units: 27/47 [57.4%] vs 
202/596 [33.9%], p<0.001; disease duration ≤15 months: 7/12 
[58.3%] vs 26/89 [29.2%], p=0.019, respectively) (figure 2A, 
C). There was no significant difference in the probability of FVC 
decline in the subgroups of patients with baseline mRSS >22/51 
units and disease duration >15 months (figure 2B, D).
Overall, 320 of 781 patients (41.0%) met the FVC-DLCO 
composite definition of lung progression (relative decrease in 
FVC ≥10%, or 5%–9% combined with DLCO ≥15%) during a 
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Figure 3 Kaplan-Meier survival plots for all-cause death during follow-up depending on the presence or absence of skin progression within 1 year 
in subgroups of patients with (A) baseline mRSS ≤22/51 units, (B) baseline mRSS >22/51 units, (C) disease duration ≤15 months and (D) disease 
duration >15 months. mRSS, modified Rodnan skin score.
median follow-up of 3.9 years (IQR 1.9–6.2 years). There were 
31 (56.4%) and 289 (39.8%) events in the skin progressor and 
non-progressor groups, respectively. Again the probability of 
FVC-DLCO decline was significantly higher for skin progressors 
than non-progressors (log-rank test p=0.004; figure 1B). In the 
subgroup of patients with low baseline mRSS, skin progressors 
also had a significantly higher probability of FVC-DLCO decline 
than non-progressors (27/47 [57.5%] vs 237/590 [40.2%]; 
p=0.002). In patients with short disease duration, skin progres-
sors had a trend towards higher probability of FVC-DLCO 
decline than non-progressors (7/11 [63.6%] vs 29/89 [32.6%]; 
p=0.050). In the subgroups of patients with baseline mRSS 
>22/51 units and disease duration >15 months, no significant 
difference was seen in the probability of FVC-DLCO decline 
between groups (online supplementary figure S1).
Systolic heart dysfunction and SRC
Despite the large patient cohort, a low number of systolic heart 
dysfunction and SRC events occurred, limiting interpretation of 
the data.
During a median follow-up of 3.2 years (IQR 1.3–5.5 years), 
15 of 662 patients (2.3%) cumulatively had an LVEF reduction. 
There were 3 (6.3%) and 12 (2.0%) events in the skin progressor 
and non-progressor groups, respectively. The probability of 
LVEF reduction was significantly higher for skin progressors 
than non-progressors (log-rank test p=0.038; online supple-
mentary figure S2A). However, there was no significant differ-
ence in the probability of LVEF reduction between patients with 
and without skin progression in any subgroup when stratified by 
either baseline mRSS or disease duration.
During a median follow-up of 3.1 years (IQR 1.6–5.6 years), 
21 of 985 patients (2.1%) cumulatively had a new SRC. There 
were 0 (0.0%) and 21 (2.3%) events in the skin progressor and 
non-progressor groups, respectively, and no significant differ-
ence in the probability of a new SRC between groups (log-rank 
test p=0.196; online supplementary figure 1). When strat-
ified by either baseline mRSS or disease duration, no signifi-
cant difference in the probability of a new SRC was observed 
between patients with and without skin progression in any 
subgroup.
Pulmonary hypertension
During a median follow-up of 3.8 years (IQR 1.9–5.8 years), 
109 of 693 patients (15.7%) developed new PH. There were 
5 (10.4%) and 104 (16.1%) events in the skin progressor and 
non-progressor groups, respectively, with no significant differ-
ence in probability of new PH between groups (log-rank test 
p=0.316; online supplementary figure S2C). When stratified by 
either baseline mRSS or disease duration, the only significant 
difference in probability of new PH between groups occurred 
in patients with disease duration >15 months, in whom skin 
progressors had a significantly lower probability of new PH 
compared with non-progressors (0/28 [0.0%] vs 89/528 [16.9%], 
respectively; p=0.026).
All-cause death
During a median follow-up of 3.4 years (IQR 1.8–5.9 years), 81 
of 1021 patients (7.9%) died. There were 12 (15.4%) and 69 
(7.3%) deaths in the skin progressor and non-progressor groups, 
respectively. The probability of all-cause death was significantly 
higher for skin progressors than non-progressors (log-rank test 
p=0.003; figure 1C). In the subgroups of patients with low base-
line mRSS and short disease duration, skin progressors also had a 
significantly higher probability of all-cause death than non-pro-
gressors (baseline mRSS ≤22/51 units: 9/67 [13.4%] vs 54/752 
[7.2%], p=0.017; disease duration ≤15 months: 4/19 [21.1%] 
vs 3/107 [2.8%], p=0.009, respectively) (figure 3A, C). In the 
subgroups of patients with baseline mRSS >22/51 units and 
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Figure 4 Kaplan-Meier survival plots for overall disease progression during follow-up depending on the presence or absence of skin progression 
within 1 year in subgroups of patients with (A) baseline mRSS ≤22/51 units, (B) baseline mRSS >22/51 units, (C) disease duration ≤15 months and (D) 
disease duration >15 months. mRSS, modified Rodnan skin score.
disease duration >15 months, there was no significant differ-
ence in probability of all-cause death between groups (figure 3B, 
D).
Overall disease progression
During a median follow-up of 4.6 years (IQR 2.2–6.6 years), 
389 of 685 patients (56.8%) cumulatively had overall disease 
progression as defined above. There were 37 (74.0%) and 
352 (55.4%) events in the skin progressor and non-progressor 
groups, respectively. The probability of overall disease progres-
sion was significantly higher for patients with skin progression 
than those without (log-rank test p=0.012; figure 1D). In the 
subgroups of patients with low baseline mRSS and short disease 
duration, skin progressors also had a significantly higher proba-
bility of overall disease progression than non-progressors (base-
line mRSS ≤22/51 units: 33/45 [73.3%] vs 283/521 [54.3%], 
p=0.010; disease duration ≤15 months: 10/11 [90.9%] vs 31/71 
[43.7%], p<0.001, respectively) (figure 4A, C). In the subgroups 
of patients with baseline mRSS >22/51 units and disease dura-
tion >15 months, no significant difference was observed in 
the probability of overall disease progression between groups 
(figure 4B, D).
Independent associations between skin progression and FVC decline 
and all-cause death
In the final multivariable Cox regression models, skin progres-
sion was independently associated with FVC decline ≥10% (HR 
1.79; 95% CI 1.20 to 2.65; p=0.004) and all-cause death (HR 
2.58; 95% CI 1.31 to 5.09; p=0.006). History of SRC, LVEF 
<45%, FVC <70%, DLCO <70% and age at baseline were 
also independently associated with all-cause death (table 2). Skin 
progression had a trend-towards association with overall disease 
progression (HR 1.40; 95% CI 0.98 to 1.99; p=0.063) (online 
supplementary table S1).
dISCuSSIOn
We investigated the association between skin progression and 
subsequent visceral organ progression in the large, prospective, 
multicentre, real-life EUSTAR cohort. Our findings indicate that 
patients with dcSSc and skin progression within 1 year have a 
higher probability of lung progression and worse survival during 
follow-up. These findings suggest that such patients should be 
monitored very carefully in clinical practice. The results also 
support the concept that inclusion of patients with lower mRSS 
or shorter disease duration can enrich clinical trials for progres-
sive skin fibrosis, and this enrichment leads to study populations 
with more severe disease at higher risk of organ progression and 
overall death. Notably, this increased risk of more severe disease 
occurs at >1 year’s follow-up and will thus not be detectable 
in a classical 1-year randomised controlled trial. Our findings 
emphasise that mRSS progression within 1 year is an appropriate 
surrogate marker for more severe disease during follow-up.
This study also provides evidence for cohort enrichment in 
clinical studies aiming primarily at lung fibrosis. Several param-
eters, including dcSSc, anti-topoisomerase 1-positive status and 
decreased baseline FVC have been identified in multiple studies 
as predictors of lung progression in SSc.20 28–34 However, few 
studies have focused specifically on patients with dcSSc. In the 
current EUSTAR analysis, skin progression was associated with 
subsequent decline of lung function in patients with dcSSc, 
even after adjustment for potentially confounding predictors. 
We examined two definitions of lung progression based on 
pulmonary function tests. The conventional definition (relative 
decrease in FVC ≥10%), based on expert group consensus, has 
been widely used as an endpoint in previous clinical studies, 
while the exploratory FVC-DLCO composite definition has 
recently been shown to predict mortality in patients with SSc-re-
lated interstitial lung disease.35 Analyses with both definitions 
produced similar results, strengthening our findings.
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Table 2 Independent factors associated with FVC decline ≥10% 
and all-cause death as determined by multivariable Cox regression
baseline characteristics Hr (95% CI)
FVC decline ≥10%
Skin progression 1.79 (1.20 to 2.65)
Age 1.00 (0.99 to 1.01)
Male sex 0.89 (0.67 to 1.19)
mRSS 1.01 (0.99 to 1.03)
Disease duration 1.00 (0.99 to 1.00)
Lung fibrosis on CT scan 1.25 (0.90 to 1.72)
Pulmonary hypertension by echocardiography 1.31 (0.93 to 1.85)
Dyspnoea NYHA stage ≥2 1.23 (0.94 to 1.62)
Joint synovitis 1.10 (0.81 to 1.49)
FVC <70% predicted 0.89 (0.64 to 1.24)
DLCO <70% predicted 1.28 (0.97 to 1.69)
Anti-Scl-70 positive 0.99 (0.75 to 1.29)
ACA positive 1.07 (0.69 to 1.66)
CRP elevation 1.22 (0.92 to 1.60)
All-cause death
Skin progression 2.58 (1.31 to 5.09)
Age 1.05 (1.03 to 1.07)
Male sex 1.56 (0.95 to 2.57)
Lung fibrosis on CT scan 1.68 (0.84 to 3.36)
Pulmonary hypertension by echocardiography 0.84 (0.47 to 1.50)
renal crisis history 3.15 (1.18 to 8.43)
Digital ulcers 1.58 (0.99 to 2.53)
Proteinuria 1.50 (0.74 to 3.04)
lVeF <45% 3.51 (1.22 to 10.12)
FVC <70% predicted 2.60 (1.49 to 4.55)
dlCO <70% predicted 2.00 (1.04 to 3.84)
Factors highlighted in bold are significantly associated with the outcome.
Skin progression is defined as an increase in mRSS >5 and ≥25% from baseline to 
12±3 months later.
ACA, anti-centromere antibody; Anti-Scl-70, anti-topoisomerase 1 antibody; CRP, 
C reactive protein; DLCO, diffusing capacity for carbon monoxide;FVC, forced vital 
capacity; LVEF, left ventricular ejection fraction;NYHA, New York Heart Association; 
mRSS, modified Rodnan skin score.
We also found that skin progression within 1 year was inde-
pendently associated with higher all-cause mortality. Previ-
ously, several prognostic studies have tried to predict mortality 
in patients with SSc. The most common baseline characteris-
tics independently associated with worse survival reported in 
different cohorts include older age, male sex, dcSSc, lung fibrosis, 
PH, systolic heart dysfunction, restrictive lung function defect, 
defective diffusing capacity of the lung, proteinuria, history of 
SRC and digital ulcers, all of which have been confirmed in 
studies derived from the EUSTAR database.21 22 36–44 We included 
these potentially significant and clinically relevant predictors in 
our multivariable Cox regression analysis, and found that skin 
progression, along with several other factors, was still an inde-
pendent prognostic factor for all-cause death.
In our cohort, average disease duration at baseline was >7 
years, indicating that most cases were not early disease. In 
subgroup analyses, we confirmed that disease course is worse in 
patients with dcSSc with early disease, although there were also 
patients with later-stage disease who showed organ progression. 
This underlines the heterogeneity of the disease course and clini-
cians should therefore pay attention to all patients with progres-
sion of skin fibrosis, even those with longer disease duration. 
Our findings are supported by the results of a study that focused 
on early dcSSc using a different definition of skin progression.23
One limitation of our analysis is the problem of missing values 
and loss to follow-up, which was inevitable in such a huge multi-
centre registry database. This partly explains the low number 
of patients during long-term follow-up. However, we tried to 
overcome this by multiple imputation before regression analysis 
and for most variables there were relatively few missing values. 
Second, we were unable to determine specific causes of death at 
all participating centres, and therefore only all-cause mortality, 
regardless of attribution to SSc, could be assessed. However, 
all-cause mortality is considered a more robust measure of disease 
outcome than SSc-associated mortality, as cause of death is often 
difficult to assign. Third, there was a relatively high proportion 
of new PH cases during follow-up in our cohort. This was the 
result of basing the definition on assessment of PH on echocar-
diography by the treating physician rather than on right heart 
catheterisation, which is required for formal diagnosis of PH. 
Unfortunately, right heart catheterisation data are not reliably 
available in the EUSTAR database, and echocardiography was 
the best available approximation of PH for the present analysis. 
Finally, as a result of the observational design, we did not eval-
uate the effect of treatment on outcomes. However, treatment 
of SSc, especially with immunosuppressive therapy, is always 
individualised and organ specific, and it is therefore difficult to 
accurately exclude the influence of treatment in an unselected 
heterogeneous cohort. In addition, there is a meaningful treat-
ment-by-indication error in observational studies, making inter-
pretation of results difficult. In our cohort, the proportions of 
patients receiving immunosuppressive treatment between groups 
at baseline were equal.
In conclusion, progressive skin fibrosis is associated with 
decline in lung function and worse survival in dcSSc during 
follow-up. The evidence-based findings obtained from the large 
prospective EUSTAR cohort allow optimisation of cohort enrich-
ment in future clinical trials aimed at skin and lung fibrosis, and 
also help clinicians to identify patients at risk of lung progression 
in clinical practice.
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